|
Males [n, %]
|
21(25.9)
|
21 (40.4)
|
4 (36.4)
|
0.2
|
16 (25.4)
|
30 (37)
|
0.23
|
|
Age [years]
|
53.5 ± 16.3
|
67.3 ± 12.7
|
50.9 ± 16.4
|
0.00001
|
48.6 ± 15.5
|
65.8 ± 12.9
|
0.000001
|
|
Graves’ disease [n, %]
|
48 (59.3)
|
8 (15.4)
|
7 (63.6)
|
0.000001
| | | |
|
Thyroidectomy in history [n, %]
|
6 (7.4)
|
0 (0)
|
1 (9.1)
|
0.12
|
2 (3.2)
|
5 (6.2)
|
0.41
|
|
Thyrostatic drugs used before RAI treatment [n, %]
|
20 (24.7)
|
15 (28.8)
|
6 (54.5)
|
0.12
|
13 (20.6)
|
28 (34.6)
|
0.06
|
|
Beta-blockers used before RAI treatment [n, %]
|
19 (23.4)
|
19 (36.5)
|
2 (18.2)
|
0.19
|
11 (17.5)
|
29 (35.8)
|
0.05
|
|
Steroids used before RAI treatment [n, %]
|
3 (3.7)
|
2 (3.8)
|
0 (0)
|
0.8
|
4 (6.3)
|
1 (1.2)
|
0.09
|
|
Orbitopathy [n, %]
|
1 (1.2)
|
0 (0)
|
0 (0)
|
0.67
|
1 (1.6)
|
0 (0)
|
0.26
|
|
Thyroid volume before RAI treatment [cm3]
|
22.6 ± 13
|
41.9 ± 22.2
|
54 ± 31.7
|
0.00001
|
24.3 ± 19.6
|
37.8 ± 21.3
|
0.000004
|
|
Thyroid volume 6 months after RAI treatment [cm3]
|
8.4 ± 12.6
|
23 ± 16.4
|
29.7 ± 20.1
|
0.00001
|
7.5 ± 9.1
|
21.4 ± 18.6
|
0.000001
|
|
Diffused nodules [n, %]
|
39 (54.9)
|
44 (84.6)
|
5 (50)
|
0.001
|
N/A
| | |
|
‘Cold’ nodules
|
1 (1.2)
|
2 (3.8)
|
1 (9)
|
0.28
|
1 (1.6)
|
3 (3.7)
|
0.44
|
|
Iodine uptake [%]
|
36.4 ± 13.4
|
30.2 ± 11.3
|
54.3 ± 16.6
|
0.00001
|
40.1 ± 14.3
|
32.2 ± 13.4
|
0.0009
|
|
Uneven iodine distribution [n, %]
|
18 (22.2)
|
26 (50)
|
4 (36.4)
|
0.004
|
4 (6.3)
|
44 (54.3)
|
0.000001
|
|
Inferior poles of the thyroid lobes reaching jugular incision [n, %]
|
3 (3.7)
|
10 (19.2)
|
3 (27.3)
|
0.006
|
3 (4.8)
|
13 (16)
|
0.03
|
|
131I− dose [MBq]
|
638.5 ± 44.2
|
658.1 ± 46.4
|
657.8 ± 64.8
|
0.035
|
624 ± 34.9
|
664.9 ± 48.4
|
0.00001
|
|
TSH concentration at presentation [μIU/ml]
|
1.5 ± 2.6
|
0.9 ± 1.7
|
0.6 ± 1
|
0.04
|
1.46 ± 2.9
|
1.08 ± 1.54
|
0.79
|
|
fT3 concentration at presentation [pg/ml]
|
4.1 ± 1.3
|
3.9 ± 1.6
|
5.6 ± 4.3
|
0.48
|
4.2 ± 1.9
|
4 ± 1.6
|
0.39
|
|
fT4 concentration at presentation [ng/ml]
|
5.5 ± 7.1
|
3.7 ± 5.1
|
2.8 ± 4.2
|
0.44
|
5.4 ± 6.8
|
4.1 ± 5.9
|
0.49
|
|
TSH concentration 6 months after RAI treatment [μIU/ml]
|
4.3 ± 5.7
|
2.3 ± 3.6
|
0.2 ± 0.25
|
0.00001
|
3.9 ± 6.5
|
2.7 ± 3.3
|
0.1
|
|
fT3 concentration 6 months after RAI treatment [pg/ml]
|
3.5 ± 1.1
|
3.9 ± 1.8
|
4.6 ± 2.3
|
0.79
|
3.8 ± 1.7
|
3.9 ± 0.9
|
0.65
|
|
fT4 concentration 6 months after RAI treatment [ng/ml]
|
3.4 ± 6.2
|
2.2 ± 3.3
|
1.9 ± 2
|
0.01
|
3.7 ± 6.6
|
2.1 ± 3.4
|
0.03
|
